An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 292-304

  Lin, Yue Zhi ^a   Shen, Rong Xian ^a   Zhu, Zhen Ying ^a   Deng, Xi Lin ^a   Cao, Xue Zhi ^a   Wang, Xue Feng ^a   Ma, Jian ^a   Jiang, Cheng Gang ^a   Zhao, Li Ping ^a   Lv, Xiao Ling ^a   Shao, Yi Ming ^b   Zhou, Jian Hua ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

EIAV; Immune response; Vaccine

Indexed keywords

ANTIBODY; EQUINE INFECTIOUS ANEMIA VIRUS ANTIBODY; EQUINE INFECTIOUS ANEMIA VIRUS VACCINE; GAMMA INTERFERON; LIVE VACCINE; NEUTRALIZING ANTIBODY; P26 ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; EQUINE INFECTIOUS ANEMIA; EQUINE INFECTIOUS ANEMIA VIRUS; FEMALE; HORSE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHINA; EQUINE INFECTIOUS ANEMIA; FEMALE; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; INTERFERON-GAMMA; MALE; VIRAL LOAD; VIRAL PROTEINS; VIRAL VACCINES; VIREMIA;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 80054863379     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.016     Document Type: Article

References (62)

1. Appay V. 25 years of HIV research!... and what about a vaccine?. Eur. J. Immunol. 2009, 39:1999-2003.
2. Baker B.M., Block B.L., Rothchild A.C., Walker B.D. Elite control of HIV infection: implications for vaccine design. Expert Opin. Biol. Ther. 2009, 9:55-69.
3. Blish C.A., Blay W.M., Haigwood N.L., Overbaugh J. Transmission of HIV-1 in the face of neutralizing antibodies. Curr. HIV Res. 2007, 5:578-587.
4. Breathnach C.C., Soboll G., Suresh M., Lunn D.P. Equine herpesvirus-1 infection induces IFN-gamma production by equine T lymphocyte subsets. Vet. Immunol. Immunopathol. 2005, 103:207-215.
5. Chung C., Mealey R.H., McGuire T.C. CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins. Virology 2004, 327:144-154.
6. Coggins L., Norcross N.L., Nusbaum S.R. Diagnosis of equine infectious anemia by immunodiffusion test. Am. J. Vet. Res. 1972, 33:11-18.
7. Cole K.S., Rowles J.L., Jagerski B.A., Murphey-Corb M., Unangst T., Clements J.E., Robinson J., Wyand M.S., Desrosiers R.C., Montelaro R.C. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 1997, 71:5069-5079.
8. Cole K.S., Paliotti M.J., Murphey-Corb M., Montelaro R.C. Maturation of envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV. J. Med. Primatol. 2000, 29:220-230.
9. Covaleda L., Fuller F.J., Payne S.L. EIAV S2 enhances pro-inflammatory cytokine and chemokine response in infected macrophages. Virology 2010, 397:217-223.
10. Craigo J.K., Montelaro R.C. EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr. HIV Res. 2010, 8:81-86.
11. Craigo J.K., Montelaro R.C. Equine infectious anemia virus infection and immunity: lessons for aids vaccine development. Future Virol. 2011, 6:139-142.
12. Craigo J.K., Leroux C., Howe L., Steckbeck J.D., Cook S.J., Issel C.J., Montelaro R.C. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J. Gen. Virol. 2002, 83:1353-1359.
13. Craigo J.K., Li F., Steckbeck J.D., Durkin S., Howe L., Cook S.J., Issel C., Montelaro R.C. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J. Virol. 2005, 79:2666-2677.
14. Cranage M.P., Whatmore A.M., Sharpe S.A., Cook N., Polyanskaya N., Leech S., Smith J.D., Rud E.W., Dennis M.J., Hall G.A. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997, 229:143-154.
15. Dyer W.B., Zaunders J.J., Yuan F.F., Wang B., Learmont J.C., Geczy A.F., Saksena N.K., McPhee D.A., Gorry P.R., Sullivan J.S. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology 2008, 5:112.
16. Farzadegan H., Chmiel J.S., Odaka N., Ward L., Poggensee L., Saah A., Phair J.P. Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4+ lymphocyte number, and AIDS-free time. J. Infect. Dis. 1992, 166:1217-1222.
17. Gil L., Alonso R., Lopez C., Blanco A., Romero Y., Guillen G., Hermida L. A CFSE-based assay of proliferative response of lymphocytes to stimulation with dengue viruses. Acta Virol. 2009, 53:147-152.
18. Gilbert P.B., Berger J.O., Stablein D., Becker S., Essex M., Hammer S.M., Kim J.H., Degruttola V.G. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis. 2011, 203:969-975.
19. Guo X., Hu J., Whitney J.B., Russell R.S., Liang C. Important role for the CA-NC spacer region in the assembly of bovine immunodeficiency virus Gag protein. J. Virol. 2004, 78:551-560.
20. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 1997, 71:3840-3852.
21. Hammond S.A., Raabe M.L., Issel C.J., Montelaro R.C. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 1999, 262:416-430.
22. Hammond S.A., Li F., McKeon B.M., Cook S.J., Issel C.J., Montelaro R.C. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J. Virol. 2000, 74:5968-5981.
23. Hanke T. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vacc. 2008, 7:303-309.
24. Harris J.E. Why we don't have an HIV vaccine, and how we can develop one. Health Aff. (Millwood) 2009, 28:1642-1654.
25. Harrold S.M., Cook S.J., Cook R.F., Rushlow K.E., Issel C.J., Montelaro R.C. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J. Virol. 2000, 74:3112-3121.
26. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C.J., Sutherland L.L., Scearce R.M., Denton C., Xia S.M., Korber B.T., Liao H.X. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 2006, 345:44-55.
27. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., Boyle R., Desrosiers R.C. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 2006, 7:19-23.
28. Kwong P.D., Mascola J.R., Nabel G.J. Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1. Cell Host Microbe 2009, 6:292-294.
29. Langemeier J.L., Cook S.J., Cook R.F., Rushlow K.E., Montelaro R.C., Issel C.J. Detection of equine infectious anemia viral RNA in plasma samples from recently infected and long-term inapparent carrier animals by PCR. J. Clin. Microbiol. 1996, 34:1481-1487.
30. Leroux C., Cadore J.L., Montelaro R.C. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?. Vet. Res. 2004, 35:485-512.
31. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 2006, 6:930-939.
32. Li F., Craigo J.K., Howe L., Steckbeck J.D., Cook S., Issel C., Montelaro R.C. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J. Virol. 2003, 77:7244-7253.
33. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., Abbink P., Coffey R.T., Grandpre L.E., Seaman M.S., Landucci G., Forthal D.N., Montefiori D.C., Carville A., Mansfield K.G., Havenga M.J., Pau M.G., Goudsmit J., Barouch D.H. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
34. Ma J., Jiang C., Lin Y., Wang X., Zhao L., Xiang W., Shao Y., Shen R., Kong X., Zhou J. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine. Arch. Virol. 2009, 154:867-873.
35. Mansfield K., Lang S.M., Gauduin M.C., Sanford H.B., Lifson J.D., Johnson R.P., Desrosiers R.C. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J. Virol. 2008, 82:4135-4148.
36. McGuire T.C., Fraser D.G., Mealey R.H. Cytotoxic T lymphocytes and neutralizing antibody in the control of equine infectious anemia virus. Viral Immunol. 2002, 15:521-531.
37. Mogensen T.H., Melchjorsen J., Larsen C.S., Paludan S.R. Innate immune recognition and activation during HIV infection. Retrovirology 2010, 7:54.
38. Montelaro R.C., Cole K.S., Hammond S.A. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res. Hum. Retroviruses 1998, 14(Suppl. 3):S255-S259.
39. Newman M.J., Issel C.J., Truax R.E., Powell M.D., Horohov D.W., Montelaro R.C. Transient suppression of equine immune responses by equine infectious anemia virus (EIAV). Virology 1991, 184:55-66.
40. Perryman L.E., O'Rourke K.I., McGuire T.C. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 1988, 62:3073-3076.
41. Piza A.S., Pereira A.R., Terreran M.T., Mozzer O., Tanuri A., Brandao P.E., Richtzenhain L.J. Serodiagnosis of equine infectious anemia by agar gel immunodiffusion and ELISA using a recombinant p26 viral protein expressed in Escherichia coli as antigen. Prev. Vet. Med. 2007, 78:239-245.
42. Prado I., Fouts T.R., Dimitrov A.S. Neutralization of HIV by antibodies. Methods Mol. Biol. 2009, 525:1-15.
43. Reynolds M.R., Weiler A.M., Weisgrau K.L., Piaskowski S.M., Furlott J.R., Weinfurter J.T., Kaizu M., Soma T., Leon E.J., MacNair C., Leaman D.P., Zwick M.B., Gostick E., Musani S.K., Price D.A., Friedrich T.C., Rakasz E.G., Wilson N.A., McDermott A.B., Boyle R., Allison D.B., Burton D.R., Koff W.C., Watkins D.I. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 2008, 205:2537-2550.
44. Robb M.L. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008, 372:1857-1858.
45. Robinson J.E., Holton D., Liu J., McMurdo H., Murciano A., Gohd R. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J. Immunol. Methods 1990, 132:63-71.
46. Rosenberg E.S., LaRosa L., Flynn T., Robbins G., Walker B.D. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol. Lett. 1999, 66:89-93.
47. Schrier R.D., Wiley C.A., Spina C., McCutchan J.A., Grant I. Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center. J. Clin. Invest. 1996, 98:731-740.
48. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Immunol. 2003, 4:835-842.
49. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008, 8:247-258.
50. Shen D.T., Gorham J.R., McGuire T.C. Enzyme-linked immunosorbent assay for detection of equine infectious anemia antibody to purified P26 viral protein. Am. J. Vet. Res. 1984, 45:1542-1543.
51. Shen T., Liang H., Tong X., Fan X., He X., Ma Y., Xiang W., Shen R., Zhang X., Shao Y. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine 2006, 24:738-749.
52. Tagmyer T.L., Craigo J.K., Cook S.J., Issel C.J., Montelaro R.C. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J. Gen. Virol. 2007, 88:1324-1336.
53. Tagmyer T.L., Craigo J.K., Cook S.J., Even D.L., Issel C.J., Montelaro R.C. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J. Virol. 2008, 82:4052-4063.
54. Valentine L.E., Watkins D.I. Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol. 2008, 16:605-611.
55. Wang X., Wang S., Lin Y., Jiang C., Ma J., Zhao L., Lv X., Wang F., Shen R., Kong X., Zhou J. Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains. Arch. Virol. 2011, 156:353-357.
56. Watkins D.I. HIV vaccine development. Top. HIV Med. 2010, 18:35-36.
57. Whitney J.B., Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 2004, 17:17-26.
58. Witkowski J.M. Advanced application of CFSE for cellular tracking. Curr. Protoc. Cytom. 2008, 25. (Chapter 9, Unit 9).
59. Wodarz D. Immunity and protection by live attenuated HIV/SIV vaccines. Virology 2008, 378:299-305.
60. Yankee T.M., Sheffer D., Liu Z., Dhillon S., Jia F., Chebloune Y., Stephens E.B., Narayan O. Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques. Virology 2009, 383:103-111.
61. Zhang W., Lonning S.M., McGuire T.C. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J. Virol. 1998, 72:9612-9620.
62. Zhang X., Wang Y., Liang H., Wei L., Xiang W., Shen R., Shao Y. Correlation between the induction of Th1 cytokines by an attenuated equine infectious anemia virus vaccine and protection against disease progression. J. Gen. Virol. 2007, 88:998-1004.